Save the date: Monday 10 June at 18.30 pm
In this webinar we will take stock of the latest pharmacological therapeutic options for hypertrophic cardiomyopathy: what's new for already consolidated treatments and promising new generation therapies.
Nadolol and Disopyramide are available again in Italy. Ranolazine, useful for angina at rest and on exertion, no longer requires a class A therapeutic plan.
Research has led to innovative cardiac myosin inhibitors such as Mavacamten and Aficamten. In Italy, for some months, Mavacamten has been made available through "compassionate use" programs, i.e. free distribution of the drug by the company, pending approval by the Italian Medicines Agency (AIFA).
We will discover the action and results of these drugs according to the AIFA protocol. The eligibility criteria, procedures and expected timescales will be presented. The webinar will offer the opportunity to ask questions in order to provide all the information necessary for a complete understanding of this important therapeutic opportunity.
Finally, a preview of AICARM's activities: the meeting in Sicily, the initiatives in Rome, Chieti and the pilot project of resuscitation courses in Milanese schools. Without forgetting the results of the "Juvenile Disadvantage" project in Florence.
Speakers
The President of AICARM, Prof. Franco Cecchi, intervenes for the scientific part of the webinar, and for the part relating to the Association's activities, the councilor Paolo Palma.
Registration
Registration is mandatory and free and can be done online. The platform used for the meeting is Zoom. It will be possible to register until the start date of the webinar.
Registration link: Sign up here